Education
About Us
Working with TipRanks
Follow Us
Bluejay Diagnostics (BJDX)
NASDAQ:BJDX
BJDX Stock Chart & Stats
$0.65
-$0.20(-5.19%)
At close: 4:00 PM EST
$0.65
-$0.20(-5.19%)
Day’s Range― - ―
52-Week Range$1.78 - $40.80
Previous CloseN/A
Volume34.54K
Average Volume (3M)5.27M
Market Cap
$1.90M
Enterprise Value-$2.05M
Total Cash (Recent Filing)$3.08M
Total Debt (Recent Filing)$142.99K
Price to Earnings (P/E)―
Beta0.30
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding972,000
10 Day Avg. Volume15,571,172
30 Day Avg. Volume5,266,425
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.16
Price to Sales (P/S)0.00
P/FCF Ratio-0.11
Enterprise Value/Market Cap-1.08
Enterprise Value/Revenue-9.51
Enterprise Value/Gross Profit148.59
Enterprise Value/Ebitda0.31
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial-scale Antibody CapacityCompleting commercial-scale IL-6 antibody production materially reduces a key manufacturing bottleneck for the Symphony cartridge. Sustained in-house antibody supply improves scalability and gross-margin potential once the platform is cleared, shortening ramp time and lowering supplier risk.
Low Financial LeverageVery low reported debt reduces near-term solvency pressure and interest burden, giving management more optionality on financing routes. This structural balance-sheet strength lowers the probability of distress compared with highly leveraged peers while the firm progresses toward commercialization.
Focused Point-of-care Diagnostics StrategyA clear product focus on rapid, near-patient immunoassays for acute care/sepsis aligns with enduring clinical demand for faster diagnostics. A differentiated, clinician-facing use case supports durable adoption potential and reimbursement pathways once performance and regulatory requirements are met.
Bears Say
Pre-commercial With No RevenueZero trailing revenue and persistent multi-million-dollar operating losses imply the business is unproven commercially. This fundamental gap forces reliance on successful clinical validation and regulatory approval to unlock revenue, making current valuation dependent on future execution rather than present cash flows.
Sustained Negative Cash FlowOngoing, material negative operating and free cash flow indicates the company cannot self-fund development and commercialization. Persistent cash burn increases the need for external capital, raising dilution risk and creating execution uncertainty over the next several quarters to years.
Regulatory Timeline Dependent On FinancingA targeted 510(k) submission in 2027 that requires additional funding creates a structural timing and execution risk. Regulatory milestones are multi-year and contingent on capital; delays or funding shortfalls would prolong commercialization, extend cash burn, and increase strategic and dilutionary uncertainty.
Bluejay Diagnostics News
BJDX FAQ
What was Bluejay Diagnostics’s price range in the past 12 months?
Bluejay Diagnostics lowest stock price was $1.78 and its highest was $40.80 in the past 12 months.
What is Bluejay Diagnostics’s market cap?
Bluejay Diagnostics’s market cap is $1.90M.
When is Bluejay Diagnostics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Bluejay Diagnostics’s earnings last quarter?
Currently, no data Available
Is Bluejay Diagnostics overvalued?
According to Wall Street analysts Bluejay Diagnostics’s price is currently Overvalued.
Does Bluejay Diagnostics pay dividends?
Bluejay Diagnostics does not currently pay dividends.
What is Bluejay Diagnostics’s EPS estimate?
Bluejay Diagnostics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bluejay Diagnostics have?
Bluejay Diagnostics has 972,000 shares outstanding.
What happened to Bluejay Diagnostics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Bluejay Diagnostics?
Currently, no hedge funds are holding shares in BJDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bluejay Diagnostics
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. The company offers the Symphony platform, a technology platform comprising the Symphony analyzer that orchestrates whole blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and the Symphony Cartridge, which includes reagents and components. It also provides the ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, the company develops Symphony IL-6 tests for the monitoring of disease progression in critical care settings. Further, it is developing additional tests for Symphony, such as tests for myocardial infraction and congestive heart failure. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Technical Analysis
Aethlon Medical
―
Venus Concept
―
Bone Biologics
―
Tivic Health Systems
―
DIH Holdings US, Inc Class A
―
Ownership Overview
―
Insiders
0.59% Mutual Funds
<0.01% Other Institutional Investors
99.41% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---